ClinicalTrials.gg
Not yet recruitingNCT07857473Updated Oct 5, 2026

A Study to Investigate the Safety and Efficacy of TE-8105 in Overweight or Obesity Participants

A Phase 2 interventional study of TE-8105 MAD Cohort 1 and TE-8105 MAD Cohort 2 in Overweight and Obesity, sponsored by Immunwork, Inc.. Not yet recruiting at 2 sites in Australia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Immunwork, Inc. · Phase 2, Interventional, and Treatment

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies in Obesity with a site in Australia — 56 open to participants now, 74 under way, 34 of them phase 3. Obesity · Australia.

Planned enrollment
80th of 168
204 · median 184
Started
2026
with 39 others
Phase 2
27 of 187
5 open now
Primary completion
2028-02
later than 39 of 73 live
Registered
183rd of 187
by date

Among the 187 studies in Obesity with a site in Australia, this one is the 80th largest by planned enrollment of the 168 interventional ones that give a count, is one of 40 that started in 2026, is one of 27 in phase 2, reaches primary completion later than 39 of the 73 other live ones, and was the 183rd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

56 of the 187 studies in Obesity with a site in Australia are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Obesity with a site in Australia, or all of them as a file.
02

Study summary

This is a Phase 2b, randomized, double-blind, placebo-controlled, multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of TE-8105 in adults with overweight or obesity, with or without weight-related health conditions.

Participants in this study will receive subcutaneous (under the skin) injections of either TE-8105 or placebo for 25 weeks. The total study duration, including screening and follow-up visits, is approximately 8 months.

Read the detailed description

TE-8105 is an injectable glucagon-like peptide-1 (GLP-1) receptor agonist designed to help manage body weight and blood sugar levels. Researchers will test different dose levels of TE-8105 compared to a placebo (an inactive substance that looks like the study drug) to find out how well TE-8105 works, how safe it is, and how the body absorbs and processes the drug over time.

A total of up to 204 eligible participants will be enrolled across 3 sequential dose-escalation cohorts (up to 68 participants per cohort). Within each cohort, participants will be randomly assigned in a 3:1 ratio to receive either TE-8105 or a matching placebo as a subcutaneous injection over a 25-week period.

An independent Safety Review Committee (SRC) will review blinded safety and PK data before approving dose escalations between cohorts and titration steps within cohorts.

A subset of participants (12 per cohort: 10 receiving TE-8105 and 2 receiving placebo) will participate in intensive PK blood sampling to evaluate how the drug is processed in the body over time.

All participants will undergo regular safety monitoring, including physical examinations, vital sign measurements, laboratory testing, 12-lead ECGs, monitoring for side effects (particularly gastrointestinal side effects), and assessments of body weight, waist and hip circumferences, body composition, and blood sugar and lipid levels.

03

Conditions studied

  • Overweight and Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's planned enrollment of 204 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Immunwork, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand the full nature, purpose, and risks of the study and provide written before starting study procedures.
  • (BMI) ≥25 and ≤34.9 kg/m², OR
  • BMI ≥25 and ≤34.9 kg/m² with at least one weight-related condition: high blood pressure (hypertension), high cholesterol or triglycerides (dyslipidemia), cardiovascular disease, or type 2 diabetes mellitus.
  • Stable body weight (less than 5% change in weight in either direction) during the screening period.
  • Medically healthy overall (apart from overweight or obesity) as determined by medical history, physical examination, vital signs, , and routine laboratory tests without abnormalities.
  • Female participants:

Must be unable to become pregnant ( for at least 12 months or surgically sterilized at least 6 weeks prior to screening), OR

If able to become pregnant: must have negative pregnancy tests at screening and before randomization, agree not to attempt pregnancy or donate eggs, and agree to use a condom combined with a highly effective method of from consent until at least 60 days after the last study dose (unless practicing complete abstinence or in a same-sex relationship).

  • Male participants:

Must agree not to donate sperm from consent until at least 120 days after the last study dose.

If sexually active with a female partner who can become pregnant, must agree to use a condom combined with highly effective birth control until at least 120 days after the last study dose.

If sexually active with a female partner who cannot become pregnant or a same-sex partner, must agree to use a condom until at least 30 days after the last study dose.

  • Have suitable veins for routine blood draws.

Exclusion criteria

Exclusion Criteria:

  • An abnormal clinical laboratory test value specified in the protocol.
  • Previous weight-loss surgery or procedures (e.g., gastric bypass, sleeve gastrectomy, gastric balloon, or intestinal sleeve) within 6 months prior to screening, or planned during the study.
  • Participation in organized weight-loss programs (e.g., WeightWatchers, Jenny Craig) or meal replacement plans within 30 days prior to screening or planned during the study.
  • Self-reported weight change of more than 5% in the 6 months prior to randomization or more than 10% in the 12 months prior to screening.
  • Exposure to any GLP-1 receptor agonist medications within 3 months prior to screening, history of allergic reactions to GLP-1 medications, or lingering effects/rebound weight gain from past GLP-1 treatments.
  • Use of prescription or over-the-counter medications intended to promote weight loss or that cause weight gain within 3 months prior to randomization.
  • Use of any diabetes medication other than metformin (e.g., insulin use is excluded).
  • Diagnosis of Type 1 diabetes, history of diabetic ketoacidosis, or hyperosmolar coma.
  • Obesity caused by other hormonal disorders (e.g., Cushing syndrome) or rare genetic conditions (e.g., Prader-Willi syndrome).
  • History or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2).
  • Uncontrolled thyroid disease, unless on a stable thyroid replacement dose for at least 3 months, or subclinical thyroid conditions that may require new treatment during the study.
  • Severe kidney impairment ( \<30 mL/min/1.73 m² or \<60 mL/min).
  • Significant liver disease, acute/chronic hepatitis, elevated liver enzymes ( > 3.0x , ALP >1.5x upper limit of normal, or >1.2x upper limit of normal), or fasting triglycerides > 500 mg/dL.
  • History of chronic pancreatitis or unexplained acute pancreatitis.
  • Gastrointestinal disorders (such as severe acid reflux or delayed stomach emptying) that could interfere with drug absorption or study participation.
  • Severe or uncontrolled heart conditions within 3 months prior to randomization (e.g., heart attack, stroke, unstable angina, or heart failure hospitalization), or Class IV severe heart failure.
  • History of irregular heart rhythms or risk factors for long syndrome (Torsade de Pointes).
  • Active cancer or history of cancer within the last 10 years (except fully removed non-melanoma skin cancer).
  • Positive screening test for , , or .
  • Active infection requiring systemically absorbed antibiotics, antivirals, or antifungals within 10 days before the first dose.
  • Active or unstable major depression or severe psychiatric disorders (such as schizophrenia or bipolar disorder) within the past 2 years. (Participants with stable depression or generalized anxiety on stable treatment may be eligible).
  • Any lifetime history of suicide attempts, or active suicidal thoughts/self-harm ideation within 2 weeks prior to or during screening.
  • History of alcohol abuse within 1 year, or regular consumption of more than 2 standard drinks per day (14 drinks per week).
  • Positive drug screen for drugs of abuse or positive alcohol breath test at screening or before the first dose.
  • Heavy smoking or nicotine use (≥6 cigarettes, cigars, vapes, or nicotine equivalents per day).
  • Unwillingness to refrain from starting new intense exercise programs (including weightlifting) from 7 days prior to Day 1 through 28 days after the final dose.
  • Unwillingness to follow dietitian advice, maintain study diaries, or refrain from using prohibited medications.
  • Females who are pregnant, breastfeeding, or planning to breastfeed.
  • Skin conditions (such as severe sunburn, deep scar tissue, large tattoos, or open sores) at potential injection sites that would interfere with dosing or site assessments.
  • Blood or plasma donation within 30 days, major blood loss (>500 mL) within 30 days, or blood transfusion within 1 year prior to first dose.
  • Participation in another clinical trial testing an drug or device within 30 days prior to screening.
  • Any active, serious medical condition with an estimated of less than 2 years, or any condition that in the investigator's judgment makes participation unsafe or non-compliance likely.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
204 participants (estimated)

Study arms

  • Experimental
    Cohort 1 TE-8105

    Administered via subcutaneous (SC) injection according to the following step-up schedule: Weeks 1-8 once weekly, Week 9 rest, Weeks 10-24 every 2 weeks.

    Drug: TE-8105 MAD Cohort 1

  • Placebo comparator
    Cohort 1 Placebo

    Administered via SC injection matching the Cohort 1 dosing schedule (Weeks 1-8 once weekly, Week 9 rest, Weeks 10-24 every 2 weeks).

    Drug: Placebo

  • Experimental
    Cohort 2 TE-8105

    Administered via SC injection according to the following step-up schedule: Weeks 1-8 once weekly, Week 9 rest, Weeks 10-24 every 2 weeks.

    Drug: TE-8105 MAD Cohort 2

  • Placebo comparator
    Cohort 2 Placebo

    Administered via SC injection matching the Cohort 2 dosing schedule (Weeks 1-8 once weekly, Week 9 rest, Weeks 10-24 every 2 weeks).

    Drug: Placebo

  • Experimental
    Cohort 3 TE-8105

    Administered via SC injection according to the following step-up schedule: Weeks 1-8 once weekly, Week 9 rest, Weeks 10-24 every 2 weeks.

    Drug: TE-8105 MAD Cohort 3

  • Placebo comparator
    Cohort 3 Placebo

    Administered via SC injection matching the Cohort 3 dosing schedule (Weeks 1-8 once weekly, Week 9 rest, Weeks 10-24 every 2 weeks).

    Drug: Placebo

Interventions

  • DrugTE-8105 MAD Cohort 1

    Administered via SC injection.

  • DrugTE-8105 MAD Cohort 2

    Administered via SC injection.

  • DrugTE-8105 MAD Cohort 3

    Administered via SC injection.

  • DrugPlacebo

    Administered via SC injection.

07

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events, including treatment-related adverse events.

    Time frame: up to 31 weeks after 1st dosing

  2. Changes from baseline in clinical laboratory assessments, physical examination findings, vital signs, and electrocardiogram (ECG) values.

    Laboratory assessments include hematology, clinical chemistry, coagulation, and urinalysis. The following 12-lead ECG parameters will be analyzed: ventricular HR, PR interval, QRS duration, QT interval, and QTcF.

    Time frame: up to 31 weeks after 1st dosing

08

Study locations

2 sites
  • Canopy Clinical Inner West
    Leichhardt, New South Wales 2040, Australia
  • Canopy Clinical Western Sydney
    Penrith, New South Wales 2750, Australia
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Feb 2028, 16 months later.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 16 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Oct 5, 2026
StartEst.
Oct 2026
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857473
Lead sponsor
Immunwork, Inc.
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Oct 2026 (estimated)
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Ya-Shan Chuang, PhD
Contact
yashan.chuang@immunwork.com
+886-2-2651-2268 ext. 512

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion